NCT06011772 2026-03-11
EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
Roswell Park Cancer Institute
Phase EARLY_PHASE1 Active not recruiting
Clinical Trials
48 trialsNCT06435351 2026-01-29
Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Recruiting
NCT05264974 2026-01-21
Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization
University of Florida
Phase 1 Recruiting
NCT01720836 2025-10-21
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
University of Pittsburgh
Phase 1/2 Recruiting
NCT06175221 2025-09-15
Autologous TLPO Vaccine Basket
Elios Therapeutics, LLC
Phase 2 Terminated
NCT06866574 2025-07-31
A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males
Xiamen University
Phase 3 Active not recruiting
NCT04523688 2025-07-22
Combi G-Vax
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Recruiting
NCT00505063 2025-06-15
Prospective Trial of Vaccine Responses in Childhood Cancer Survivors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT06522919 2025-01-28
CombiCoR-Vax
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Recruiting
NCT01973322 2025-01-09
ABSIDE
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Completed
NCT03092453 2024-12-24
Dendritic Cell Vaccination in Patients With Advanced Melanoma
University of Pennsylvania
Phase 1 Completed
NCT03946358 2024-12-20
VolATIL
Centre Hospitalier Universitaire de Besancon
Phase 2 Completed
NCT04487756 2024-04-03
VENEZO-LUNG
Instituto Oncológico Dr Rosell
Phase 1/2 Active not recruiting
NCT03629886 2024-03-15
Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study
GlaxoSmithKline
Phase 4 Completed
NCT06207175 2024-01-23
A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine
Beijing Health Guard Biotechnology, Inc
Phase 3 Unknown
NCT05986981 2023-08-14
MUC1 Therapeutic Tumor Vaccine in Advanced Solid Cancers
Peking Union Medical College Hospital
Phase 2 Unknown
NCT04965350 2023-04-13
Lot Consistency Clinical Trial of Bivalent HPV Vaccine in 9 to 30 Years Old Healthy Females
Shanghai Zerun Biotechnology Co.,Ltd
Phase 3 Completed
NCT05694728 2023-01-23
A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine
Beijing Health Guard Biotechnology, Inc
Phase 2 Completed
NCT05680454 2023-01-17
A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine
Beijing Health Guard Biotechnology, Inc
Phase 1 Completed
NCT05672966 2023-01-06
Phase I Clinical Trial of a Candidate HPV Vaccine
Wuhan BravoVax Co., Ltd.
Phase 1 Unknown
NCT05668572 2023-01-04
A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine
Beijing Health Guard Biotechnology, Inc
Phase 3 Unknown
NCT05662020 2022-12-27
A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China
Beijing Health Guard Biotechnology, Inc
Phase 3 Active not recruiting
NCT01730118 2022-09-10
Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02529930 2022-07-13
An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3)
Nykode Therapeutics ASA
Phase 1/2 Completed
NCT05426148 2022-06-29
Lot Consistency Clinical Trial of of Recombinant HPV Bivalent Vaccine in 9 to14 Years Old Healthy Female
Xiamen Innovax Biotech Co., Ltd
Phase 4 Completed
NCT01798056 2021-05-13
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy
GlaxoSmithKline
Phase 3 Completed
NCT01031069 2020-07-21
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
GlaxoSmithKline
Phase 4 Completed
NCT01896869 2020-05-19
FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02431572 2020-04-28
A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy
Massachusetts General Hospital
Phase NA Completed
NCT00684294 2020-03-02
Auto TAG
Mary Crowley Medical Research Center
Phase 1 Terminated
NCT02566265 2019-01-30
SHIVERING 2
Yale University
Phase 2 Completed
NCT01984697 2018-08-08
V503-010
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00988559 2018-07-09
Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT03525652 2018-05-16
Therapeutic Vaccine Plus PD-1 Knockout in Prostate Cancer Treatment
The First Affiliated Hospital of Guangdong Pharmaceutical University
Phase 1/2 Unknown
NCT02332889 2018-05-04
Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs
University of Louisville
Phase 1/2 Terminated
NCT01042535 2018-04-11
Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT00654030 2018-04-09
Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer
University of Kentucky
Phase 2 Completed
NCT00405327 2017-11-06
A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT02745756 2017-08-30
A Combined Cell Therapy Approach to the Treatment of Neuroblastoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Withdrawn
NCT00819806 2017-07-31
CpG 7909/Montanide ISA 720 With or Without Cyclophosphamide in Combination Either With NY-ESO-1-derived Peptides or the NY-ESO-1 Protein for NY-ESO-1-expressing Tumors
University of Pittsburgh
Phase 1 Completed
NCT01483274 2017-05-09
AML
University of Louisville
Phase 1 Withdrawn
NCT01302821 2017-02-23
C11 AMT Positron Emission Tomography (PET) Imaging in Patients With Metastatic Invasive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Withdrawn
NCT01205581 2016-09-23
Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV
St. Jude Children's Research Hospital
Phase 2 Completed
NCT00501137 2015-04-10
BCGov-01
University of British Columbia
Phase 3 Completed
NCT00325130 2015-03-12
Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01829373 2013-04-11
Lung Cancer Vaccine Plus Oral Dietary Supplement
University of Kentucky
Phase 1 Completed
NCT01512784 2012-01-19
Long Term Immunogenicity of Quadrivalent Human Papillomavirus Vaccine (Gardasil®)in HIV-infected Adolescents and Young Adults
University of Milan
Phase 3 Unknown
NCT01022905 2010-03-01
Vaccine Responses to Influenza A H1N1/09 Immunization in High-risk Patients
University Hospital, Geneva
Phase 4 Completed